Biotech Startups

ILiAD Biotechnologies is a clinical-stage biotechnology company developing vaccines and treatments for disease caused by Bordetella pertussis, with a lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials. It operates a wholly-owned subsidiary, BioLyo Technologies, a contract development and manufacturing organization for live bacterial products based in Ghent, Belgium.

1 investor

Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.

1 investor

1 investor

Illumacell is a clinical-stage biotech company developing a non-invasive photodynamic therapy for cancer, combining its patented "Wall-of-Light" medical light device with the off-patent drug 5-ALA to destroy tumor cells at depth without surgery. It is pursuing Oral Potentially Malignant Disorders as a lead indication and is conducting early-stage clinical studies in Canada.

1 investor

Illume Labs aggregates data from wearables, blood tests, and genomic sequencing to deliver personalized health insights via text message and conversational AI, helping users understand changes in their health metrics and receive actionable recommendations.

1 investor

Illuminare Bio develops Illuminare-1, a fluorescent imaging agent that makes peripheral nerves visible during surgery to help surgeons avoid nerve injury. The product is administered intravenously pre-operatively and works with standard surgical equipment across multiple procedure types including prostatectomy, mastectomy, hernia repair, and spinal surgery.

1 investor

1 investor

ImageCyte develops precision nanowell plate technology that prepares cells, organoids, and model organisms for imaging, aiming to improve imaging quality, reproducibility, and throughput. Its tools serve cell research and biological discovery workflows, focusing on the physical interface between samples and existing imaging instrumentation.

1 investor

Imagene develops AI-based oncology intelligence that turns cancer data into insights to support patient care and drug development. It serves the biotech and clinical oncology market, working with scientists, physicians, and therapy developers.

1 investor

Imagene Labs provides a cloud-based genetic analytics platform for healthcare services and wellness brands that delivers personalized product recommendations based on customers' DNA analysis using ethnically-relevant reference datasets. The platform covers traits including aging, fitness, nutrition, skin health, and children's health, and is compliant with Singapore's data protection standards.

1 investor

1 investor

Imaginab develops advanced imaging solutions for immuno-oncology that visualize immune cell activity and treatment response without invasive biopsies. The company serves oncologists and clinical researchers seeking non-invasive alternatives for patient monitoring and treatment decision-making.

1 investor

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments. It has operated for over 130 years and serves patients and healthcare needs globally.

1 investor

IMAI develops 3D histology technology for early and accurate diagnosis of cancer to improve therapeutic outcomes and patient care in oncology.

1 investor

Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.

1 investor

IMBRUVICA is a prescription cancer medication (available as capsules, tablets, and oral suspension) used to treat B-cell malignancies such as CLL/SLL and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease in adults and children. It is marketed by AbbVie, and the page provides patient dosing instructions, safety warnings, and side-effect information.

1 investor

An enterprise that develops and commercializes biomedical materials and biopharmaceutical products, including Class III and Class II medical devices, dermal fillers, facial threads, and proteins/peptides for medical aesthetics, dermatology, surgery, metabolic disease, and professional skincare.

1 investor

Imhotex is a biotech company focused on drug development, managed by experienced professionals in therapeutic discovery and clinical advancement. The company appears to focus on translating scientific research into novel drug candidates.

1 investor

IMIDomics develops a patient data-driven clinical discovery platform to identify drug targets for immune-mediated inflammatory diseases (IMIDs), building on 17+ years of research and data from over 17,000 IMID patients. The company combines deep immunology expertise with computational analysis to discover first-in-class therapeutics for diseases like rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.

1 investor

ImmPro provides top-down proteomics analytical services for biopharmaceutical development, using single-particle protein analysis to characterize proteins and proteoforms. Its offerings support gene therapy vector characterization, biomarker discovery, and disease-specific assays for areas such as neurodegeneration, oncology, and cardiometabolic disease.

1 investor

ImmuneSpecs uses immunopeptidomics (MAPPs) technology to identify peptides presented by MHC molecules, enabling precise mapping of T cell epitopes in biotherapeutics and validation of immunotherapy targets. The company serves biopharmaceutical organizations seeking advanced antigen presentation analysis.

1 investor

IMMUNETHEP is a biotechnology company, spun off from the University of Porto, developing immunology-based technology originating from the Laboratory of Immunology of ICBAS. It conducts R&D from its facilities at Biocant Park in Cantanhede, Portugal.

1 investor

Immunicom is a biotech company developing immunotherapies based on its Immunopheresis platform, a blood-filtering device that works external to the body to treat cancer and inflammatory, cardiovascular, renal, and autoimmune diseases. Its initial focus is immuno-oncology, with CE Mark approval in Europe for advanced triple-negative breast cancer and multiple ongoing clinical trials.

1 investor

Immunique is a science-based biotech company developing cell therapies that restore balance in the immune system to treat disease and support long-term patient recovery. Its research focuses on immune cell function and is aimed at extending healthy lifespan through clinical- and data-driven treatment strategies.

1 investor